Summary
TNF-α may improve drug delivery to tumors by alteration of vascular permeability. However, toxicity precludes its systemic administration in patients. NGR-TNF comprises TNF coupled to the peptide CNGRC, which is a ligand for CD13. CD13 is expressed on tumor vasculature. Therefore, to assess the efficacy of NGR-TNF its biological effect on tumor vasculature should be measured rather than its effect on tumor growth. The aim of this study was to assess the effects of a low dose of NGR-TNF (5 ng/kg) on vascular permeability, tumor hypoxia, perfusion and proliferation in lymphoma bearing mice. MRI measurements with blood pool contrast agent showed an increased leakage of the contrast agent from the vasculature in NGR-TNF treated tumors compared with controls (p < 0.05), suggesting NGR-TNF-induced vascular permeability. Immunohistochemical analysis two hours after NGR-TNF treatment showed a decrease in tumor hypoxia (p < 0.1) and an increase in labeling index of the S-phase marker bromodeoxyuridine (p < 0.1), possibly due to an increase in tumor blood flow after NGR-TNF treatment. Although a decrease in tumor hypoxia and an increase in labeling index could have lead to increased tumor growth, in this experiment after one day a decrease in tumor volume was measured. Possibly, the effects on tumor hypoxia and proliferation two hours after treatment are transient and overruled by other, more longlasting effects. For example, the observed increase in vascular permeability may lead to haemoconcentration and increased interstitial pressure, ultimately resulting in an reduction of tumor blood flow and thus a decrease in tumor growth. A beneficial effect of NGR-TNF in combination with other therapeutical agents may therefore critically depend on the sequence and timing of the regimens. Currently, NGR-TNF is being tested in clinical studies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL: TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82:973–980, 2000
Kristensen CA, Nozue M, Boucher Y, Jain RK: Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 74:533–536, 1996
Suzuki S, Ohta S, Takashio K, Nitanai H, Hashimoto Y: Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. Int J Cancer 46:1095–1100, 1990
Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 14:2653–2665, 1996
Lejeune FJ: High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer. Eur J Cancer 31A:1009–1016, 1995
Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A: Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18:1185–1190, 2000
Curnis F, Sacchi A, Corti A: Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 110:475–482, 2002
Kauppinen RA: Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 15:6–17, 2002
Duvvuri U, Poptani H, Feldman M, Nadal-Desbarats L, Gee MS, Lee WM, Reddy R, Leigh JS, Glickson JD: Quantitative T1rho magnetic resonance imaging of RIF-1 tumors in vivo: Detection of early response to cyclophosphamide therapy. Cancer Res 61:7747–7753, 2001
Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM: NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40:793–799, 1998
Le Duc G, Peoc'h M, Remy C, Charpy O, Muller RN, Le Bas JF, Decorps M: Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med 42:754–761, 1999
Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps M: Vessel size imaging. Magn Reson Med 45:397–408, 2001
Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, Heerschap A, Stubbs M, van der Kogel AJ, Griffiths JR: Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 17:445–454, 2003
Bremer C, Mustafa M, Bogdanov A, Jr., Ntziachristos V, Petrovsky A, Weissleder R: Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology 226:214–220, 2003
Pathak AP, Rand SD, Schmainda KM: The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (DeltaR2*) and contrast agent (MION) dose. J Magn Reson Imaging 18:397–403, 2003
Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A: Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 57:1922–1928, 1997
Raleigh JA, Franko AJ, Treiber EO, Lunt JA, Allen PS: Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: Detection by F-19 nuclear magnetic resonance at 2.35 T. Int J Radiat Oncol Biol Phys 12:1243–1245, 1986
Raleigh JA, Miller GG, Franko AJ, Koch CJ, Fuciarelli AF, Kelly DA: Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer 56:395–400, 1987
Durand RE, Raleigh JA: Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 58:3547–3550, 1998
Arteel GE, Thurman RG, Yates JM, Raleigh JA: Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br J Cancer 72:889–895, 1995
Raleigh JA, Chou SC, Arteel GE, Horsman MR: Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151:580–589, 1999
Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, van der Kogel AJ: Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 48:1529–1538, 2000
Cline JM, Thrall DE, Page RL, Franko AJ, Raleigh JA: Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br J Cancer 62:925–931, 1990
Azuma C, Raleigh JA, Thrall DE: Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res 148:35–42, 1997
Westphal JR, van't Hullenaar RG, van der Laak JA, Cornelissen IM, Schalkwijk LJ, van Muijen GN, Wesseling P, de Wilde PC, Ruiter DJ, de Waal RM: Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 76:561–570, 1997
Bussink J, Kaanders JH, Rijken PF, Martindale CA, van der Kogel AJ: Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br J Cancer 77:57–64, 1998
Rijken PF, Bernsen HJ, van der Kogel AJ: Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 50:141–153, 1995
Kallinowski F, Schaefer C, Tyler G, Vaupel P: In vivo targets of recombinant human tumour necrosis factor-alpha: Blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 60:555–560, 1989
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Jr., Shepard HM: Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230:943–945, 1985
Kaanders JH, Bussink J, van der Kogel AJ: ARCON: A novel biology-based approach in radiotherapy. Lancet Oncol 3:728–737, 2002
Author information
Authors and Affiliations
Corresponding author
Additional information
HvL and GG contributed equally to this work.
Rights and permissions
About this article
Cite this article
van Laarhoven, H.W.M., Gambarota, G., Heerschap, A. et al. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs 24, 27–36 (2006). https://doi.org/10.1007/s10637-005-4540-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-4540-2